Novel agents for the treatment of pancreatic adenocarcinoma

Haiying Cheng, Eirini Merika, Kostas N. Syrigos, Muhammad Wasif Saif

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

There are urgent needs to develop novel and more effective regimens to improve outcomes of pancreatic cancer given its dismal prognosis and limited treatment options. Several phase I clinical trials involving novel agents were recently presented at the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting. It appears that hedgehog inhibition with IPI-926 was welltolerated and might be effective in treating pancreatic cancer when combined with gemcitabine. The survival benefits will be tested in the following randomized phase II trial. The new combination of gemcitabine and blockade of checkpoint kinases with AZD7762 showed an acceptable safety profile. Furthermore, inhibition of PI3K by BAY80-6946 was well tolerated with PET-CT suggesting reduction in FDG uptake in some pancreatic cancer. The benefits of above novel agents/regimens need to be further tested in phase II trials.

Original languageEnglish (US)
Pages (from-to)334-338
Number of pages5
JournalJournal of the Pancreas
Volume12
Issue number4
StatePublished - Jul 2011
Externally publishedYes

Fingerprint

gemcitabine
Pancreatic Neoplasms
Adenocarcinoma
Clinical Trials, Phase I
Phosphatidylinositol 3-Kinases
Phosphotransferases
Safety

Keywords

  • Adenocarcinoma
  • Checkpoint kinase 1
  • Checkpoint kinase 2
  • Clinical Trials
  • Hedgehog Proteins
  • Pancreatic Neoplasms
  • Phase I as Topic /adverse effects
  • Protein Kinases
  • Protein-Serine-Threonine Kinases

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Hepatology

Cite this

Cheng, H., Merika, E., Syrigos, K. N., & Saif, M. W. (2011). Novel agents for the treatment of pancreatic adenocarcinoma. Journal of the Pancreas, 12(4), 334-338.

Novel agents for the treatment of pancreatic adenocarcinoma. / Cheng, Haiying; Merika, Eirini; Syrigos, Kostas N.; Saif, Muhammad Wasif.

In: Journal of the Pancreas, Vol. 12, No. 4, 07.2011, p. 334-338.

Research output: Contribution to journalArticle

Cheng, H, Merika, E, Syrigos, KN & Saif, MW 2011, 'Novel agents for the treatment of pancreatic adenocarcinoma', Journal of the Pancreas, vol. 12, no. 4, pp. 334-338.
Cheng H, Merika E, Syrigos KN, Saif MW. Novel agents for the treatment of pancreatic adenocarcinoma. Journal of the Pancreas. 2011 Jul;12(4):334-338.
Cheng, Haiying ; Merika, Eirini ; Syrigos, Kostas N. ; Saif, Muhammad Wasif. / Novel agents for the treatment of pancreatic adenocarcinoma. In: Journal of the Pancreas. 2011 ; Vol. 12, No. 4. pp. 334-338.
@article{a7b8d12e53624031800e9cb8420ae0c4,
title = "Novel agents for the treatment of pancreatic adenocarcinoma",
abstract = "There are urgent needs to develop novel and more effective regimens to improve outcomes of pancreatic cancer given its dismal prognosis and limited treatment options. Several phase I clinical trials involving novel agents were recently presented at the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting. It appears that hedgehog inhibition with IPI-926 was welltolerated and might be effective in treating pancreatic cancer when combined with gemcitabine. The survival benefits will be tested in the following randomized phase II trial. The new combination of gemcitabine and blockade of checkpoint kinases with AZD7762 showed an acceptable safety profile. Furthermore, inhibition of PI3K by BAY80-6946 was well tolerated with PET-CT suggesting reduction in FDG uptake in some pancreatic cancer. The benefits of above novel agents/regimens need to be further tested in phase II trials.",
keywords = "Adenocarcinoma, Checkpoint kinase 1, Checkpoint kinase 2, Clinical Trials, Hedgehog Proteins, Pancreatic Neoplasms, Phase I as Topic /adverse effects, Protein Kinases, Protein-Serine-Threonine Kinases",
author = "Haiying Cheng and Eirini Merika and Syrigos, {Kostas N.} and Saif, {Muhammad Wasif}",
year = "2011",
month = "7",
language = "English (US)",
volume = "12",
pages = "334--338",
journal = "Journal of the Pancreas",
issn = "1590-8577",
publisher = "E.S. Burioni Ricerche Bibliografiche",
number = "4",

}

TY - JOUR

T1 - Novel agents for the treatment of pancreatic adenocarcinoma

AU - Cheng, Haiying

AU - Merika, Eirini

AU - Syrigos, Kostas N.

AU - Saif, Muhammad Wasif

PY - 2011/7

Y1 - 2011/7

N2 - There are urgent needs to develop novel and more effective regimens to improve outcomes of pancreatic cancer given its dismal prognosis and limited treatment options. Several phase I clinical trials involving novel agents were recently presented at the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting. It appears that hedgehog inhibition with IPI-926 was welltolerated and might be effective in treating pancreatic cancer when combined with gemcitabine. The survival benefits will be tested in the following randomized phase II trial. The new combination of gemcitabine and blockade of checkpoint kinases with AZD7762 showed an acceptable safety profile. Furthermore, inhibition of PI3K by BAY80-6946 was well tolerated with PET-CT suggesting reduction in FDG uptake in some pancreatic cancer. The benefits of above novel agents/regimens need to be further tested in phase II trials.

AB - There are urgent needs to develop novel and more effective regimens to improve outcomes of pancreatic cancer given its dismal prognosis and limited treatment options. Several phase I clinical trials involving novel agents were recently presented at the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting. It appears that hedgehog inhibition with IPI-926 was welltolerated and might be effective in treating pancreatic cancer when combined with gemcitabine. The survival benefits will be tested in the following randomized phase II trial. The new combination of gemcitabine and blockade of checkpoint kinases with AZD7762 showed an acceptable safety profile. Furthermore, inhibition of PI3K by BAY80-6946 was well tolerated with PET-CT suggesting reduction in FDG uptake in some pancreatic cancer. The benefits of above novel agents/regimens need to be further tested in phase II trials.

KW - Adenocarcinoma

KW - Checkpoint kinase 1

KW - Checkpoint kinase 2

KW - Clinical Trials

KW - Hedgehog Proteins

KW - Pancreatic Neoplasms

KW - Phase I as Topic /adverse effects

KW - Protein Kinases

KW - Protein-Serine-Threonine Kinases

UR - http://www.scopus.com/inward/record.url?scp=79960266140&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960266140&partnerID=8YFLogxK

M3 - Article

VL - 12

SP - 334

EP - 338

JO - Journal of the Pancreas

JF - Journal of the Pancreas

SN - 1590-8577

IS - 4

ER -